Targeting uracil-DNA glycosylases for therapeutic outcomes using insights from virus evolution by Savva, Renos
BIROn - Birkbeck Institutional Research Online
Savva, Renos (2019) Targeting uracil-DNA glycosylases for therapeutic
outcomes using insights from virus evolution. Future Medicinal Chemistry
11 (11), ISSN 1756-8919.
Downloaded from: http://eprints.bbk.ac.uk/27376/
Usage Guidelines:
Please refer to usage guidelines at http://eprints.bbk.ac.uk/policies.html or alternatively
contact lib-eprints@bbk.ac.uk.
		
Targeting uracil-DNA glycosylases for therapeutic outcomes using insights from 
virus evolution. 
 
Renos Savva 
Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck, University of London, Malet Street, London 
WC1E 7HX, UK. +44 (0)20 7631 6805 r.savva@mail.cryst.bbk.ac.uk 
 
Ung-type uracil-DNA glycosylases are frontline defenders of DNA sequence fidelity in bacteria, plants, 
and animals; Ungs also directly assist both innate and humoral immunity. Critically important in viral 
pathogenesis, whether acting for or against viral DNA persistence, Ungs also have therapeutic 
relevance to cancer, microbial, and parasitic diseases. Ung catalytic specificity is uniquely conserved, 
yet selective antiviral drugging of the Ung catalytic pocket is tractable. However, more promising 
precision therapy approaches present themselves via insights from viral strategies, including 
sequestration or adaptation of Ung for non-canonical roles. A universal Ung inhibition mechanism, 
converged upon by unrelated viruses, could also inform design of compounds to inhibit specific distinct 
Ungs. Extrapolating current developments, the character of such novel chemical entities is proposed. 
 
Executive Summary 
• Introduction 
  Ungs are essential enzymes at the forefront of pathogenic states, both   
  defending cells and being co-opted by pathogens. 
• Ung structure and mechanism 
  Ung is an exquisitely specific catalytic domain, but pre-catalytic variations   
  promise specificity between targeting the host enzyme and pathogenic variants. 
• Origins and significance of uracil-substituted DNA in pathogenesis 
Viruses have evolved to silence, or co-opt Ung to facilitate pathogenic states. 
Understanding these origins allows search for novel Ung-interacting proteins. 
Knowledge of Ung-interacting protein interfaces can facilitate drug discovery. 
• Motivations and contexts for therapeutic interventions targeting Ung 
Understanding the significance of Ung in diverse pathogenic states permits suitable 
intervention to be designed and implemented. 
• Convergence on a universal Ung-inhibitory mechanism by unrelated virus proteins 
Natural protein-protein interactions that irreversibly inhibit Ung activity, by convergence 
on a common mechanism have independently evolved at least 3 times from different 
protein architectures. 
The naturally evolved inhibitor proteins do not target uracil specificity of Ung. 
• Synthetic selective Ung inhibition and future trends 
Drug design centred upon uracil-analogues has shown specificity is achievable. 
Compounds featuring uracil and hydrophobic tails are not ideal drug candidate 
molecules. 
Compounds targeting Ung protein-protein interactions have shown selective potency 
against poxviruses. 
• Conclusions 
Eschewing uracil-specificity to emulate features of natural protein-protein interactions, 
promises novelty in selective drug discovery to target Ungs in pathogenic states.  
		
Introduction 
Ung is on the frontline of DNA repair 
Ung, is the archetypal uracil-DNA glycosylase and the first enzyme to be described with a role in DNA 
damage repair [1,2]. Ung is a DNA binding protein with its primary and ostensible role in limitation of 
DNA damage, via rapid and exquisite deoxyuridine-triggered initiation of the base excision repair (BER) 
response [3,4]. One of the most frequent DNA mutation events is the conversion of cytosine residues in 
DNA, to uracil, by spontaneous hydrolytic deamination [5]. Unless this mutation is corrected prior to 
replication, a cytosine to thymine transition mutation will be recorded upon replication. All cells must 
therefore contain an enzyme capable of recognising uracil in DNA, and efficiently removing it, to ensure 
the longevity of DNA fidelity. 
For Ung-processed DNA, repair is just one possible fate  
Ung is also known to play a role in the cellular response to pathogens. Ung is described as a frontline 
defence molecule providing innate immunity in both eukaryotes and prokaryotes, in which it may act as 
a restriction enzyme on uracil-substituted viral DNA [6,7]. Ung is furthermore recruited to an essential 
role in humoral immune system development and maturation processes in mammals: Somatic 
hypermutation (SHM), and, Class Switch Recombination (CSR) [8,9]. It is therefore unsurprising that 
during active pathogenesis, host cellular Ungs are found to be variously repurposed or targeted by 
viruses, or else specialised Ung variants are encoded by viruses: These themes will be explored in this 
article. Given the varied role of Ungs in pathogenesis, endeavours to develop inhibitors directed 
towards the uracil binding pocket in the catalytic centre of the enzyme [10-15], would appear obvious. 
Targeting Ungs need not involve uracil analogues 
Uracil or its analogues however, as will be discussed in this article, may not be the only route to 
developing selectivity against Ung. Not least because the catalytic pocket is highly conserved in 
described structures of the Ung catalytic domain. Therefore, development of selective novel chemical 
entities targeting other identified characteristics of Ungs, such as the uniquely shaped DNA binding cleft 
or catalytically important features distal to the catalytic pocket, may provide a lower barrier and a wider 
range of possibilities for drug development. Consideration of other Ung contexts, including their known 
protein-protein interactions (PPIs), provides additional perspectives from which to inform development 
routes for drugs to target any particular Ung. 
Naturally informed routes to selective Ung-inhibitor design 
Considerations for targeting Ungs in drug discovery include the fact that some viruses encode Ung 
variants of their own. In spite of a high degree of conservation between all Ungs, quite reasonable initial 
selectivity with novel chemical entities based upon uracil-analogues has been shown [10-15]. However, 
developing these to the point where they show no off-target effects will be challenging, given that uracil-
specificity is not greatly variant across known Ungs. Furthermore, achieving favourable toxicity profiles 
may prove just as challenging, given the potential of uracil analogues to intercalate in DNA. Finally, in 
pursuit of selectivity, the targeting of variant hydrophobic crevices interior to the enzyme via the uracil-
specificity pocket [12-14] presents drug design challenges of its own, in terms of solubility profiles. 
Therefore, looking instead at features not involving uracil-specificity could prove more favourable, as 
will be explored in this article. 
One of the conserved motifs essential for Ung catalysis is located outside the uracil-specificity pocket, 
and is more sequence diverse between evolutionarily distinct Ungs. This sequence variation has been 
observed to underlie structural dissimilarity and mechanistic differences, with relevance to 
pathogenesis. This opens the door to selectivity, therefore Ung could be targeted in cancers, microbial 
pathogens, and parasites, to potentiate the action of other drugs. Also, virally encoded Ungs present 
non-enzymatic features involved in PPIs that are important to the virus survival strategies. Viruses that 
do not encode Ung, but that manipulate the host enzyme to their advantage, similarly rely on PPIs to 
achieve those ends. 
		
Another rationale relevant to drug targeting of Ungs, is to note that naturally evolved strategies to 
silence Ung activity do not target the uracil-specificity of these enzymes. Instead, sequestration and 
inhibition of Ung, is via Ung-specific DNA mimetic contacts from viral proteins [16-21]. Viral antagonism 
to greatly limit or silence Ung activity, is mediated via depletion or physiologically irreversible 
sequestration of Ung. The genes for Ung inhibitory proteins have their origins in evolutionarily distinct 
types of viruses, whether infecting prokaryotes or eukaryotes [22-25]. These inhibitory proteins 
populate architecturally discrete classes, and even within a single class there is significant sequence 
variation: To the point that it is not straightforward to search for potential structural relatives in other 
genomes. It is of note that the poxviruses encode an Ung that has a key structural variation in the 
essential pre-catalytic loop, rendering it immune to these virally evolved inhibitors (reviewed in [26]). 
Any of the presently known viral inhibitor proteins will nevertheless inhibit any compliant Ung, albeit with 
individual variation in the finer chemical details of the association. 
The potential is that novel chemical entities developed to exploit aspects of this universal mechanism of 
Ung inhibition, could be diverse in design and in the details of their action. These could be made highly 
specific to any individual Ung of interest, and there is no reason why this could not include any outliers, 
such as Ung encoded by poxvirus, or b-herpesviruses. Of relevance to the wider scope of this article, 
poxvirus Ung forms a druggable PPI with the viral DNA polymerase (the unique properties of poxvirus 
Ung, and its association with the viral polymerase are reviewed in [26,27]) [28]. 
The remainder of this article will therefore consider in more detail: (1) Ung structure and mechanism, 
(2) origins and significance of uracil-substituted DNA in pathogenesis (3) motivations and contexts for 
therapeutic interventions targeting Ung, (4) a universal mechanism for Ung inhibition by architecturally 
unrelated proteins encoded by viruses, and (5) the known Ung inhibitory synthetic compounds reported 
to date. To conclude, the broader context and future synthetic possibilities for drugging Ung selectively 
in light of this information will be considered. 
1 Ung structure and mechanism, a slight comparison 
For the purposes of this overview, Ung structure and mechanism will be considered essentially 
universal, with limited examples selected to highlight differences in certain pathogens versus the 
human enzyme. Also, for the purposes of this article, unless specifically referring to the human nuclear 
isoform UNG2, the Ung catalytic domain will be referred to universally as ‘Ung’. 
Ungs (KEGG orthology: K03648) were the first described, and are the most ubiquitous, type of the 
uracil-DNA glycosylase (UDG) superfamily of DNA N-glycosidic hydrolases (EC: 3.2.2.27). Thus, Ungs 
comprise family branch 1 in the UDG superfamily. The UDG superfamily has at least 6 major branches, 
with general conservation of motifs important to ligand binding, substrate selectivity and catalysis, as 
well as overall architectural similarities especially at the catalytic centre (comprehensively reviewed in 
[29]). New variants of almost all UDG families are regularly reported in the literature [30,31], including 
variants of family 1 enzymes (i.e. Ungs) [32,33]. Ung variants from pathogens may have relevance as 
targets for therapeutics development to combat pathogenesis [26-28,34-37], and in some cases novel 
chemical entities of interest have been reported [10,11,14,28,38] (Table 1). 
Table 1 Variant Ungs encoded by pathogen genomes, with properties of relevance to drug discovery. 
Pathogen Ung structural variant Identified difference with respect to UNG2 
Herpesvirus (a- / HSV-1) Shorter pre-catalytic loop; uracil-analogue inhibitors described [10,11,14]. 
Herpesvirus (b- / HCMV, 
Roseolavirus) 
Significantly variant pre-catalytic loop; no structural information or inhibitors described to 
date. 
Herpesviruses (g- / EBV, KSHV) Elongated/structured pre-catalytic loop is essential to replication [34,35]. 
Poxviruses [vaccinia] Divergent features/ variant pre-catalytic loop, resistant to phage-mediated inhibition; potent 
PPI inhibitors identified [26-28]. 
Mycobacterium tuberculosis Atypical catalytic structure, weakened phage-mediated inhibition [36,37]. 
Plasmodium falciparum Divergent sequence; uracil-analogue inhibitors identified [38]. 
		
In pathogen encoded Ungs, structures are sufficiently diverged in important catalytic respects, that their 
selective inhibition might present more options for drug design. For example, the variants encoded by 
g-herpesviruses are sufficiently different in important respects with regard to catalysis as to present 
unique possibilities for their selective inhibition (Table 1, Figure 1, Figure 2) [33,34]. Another example of 
a significantly variant Ung, is that encoded by vaccinia virus. Importantly the vaccinia Ung is 
indispensable to viral replication [39] (vaccinia Ung is reviewed in [26,27]). In the description that 
follows, the Ung catalytic domain is the inferred canonical structural form of UDG family 1. 
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Figure 1 The Ung domain makes specific contacts to dsDNA, some of which are mimicked by viral Ung-inhibitory proteins. Structure 
cartoons, for illustration, rendered in Chimera*: 
A - 1SSP, B - 1UGH (UNG2 complexes with respectively, dsDNA, and Ugi from Bacillus phage PBS1). 
C – g-herpesvirus Ung complexes: 5NNU (KSHV [HHV-8] with dsDNA), chains A, S and T only; D – 2J8X (EBV [HHV-4] with Ugi from 
Bacillus phage PBS1), chains A and B only. 
Poses in panel B, and C are relative to panel A, via structure match to chain E from 1SSP. In panel B, pose is relative to panel D, via 
structure match to chain B from 2J8X. 
The Ung minor groove DNA binding loop is shown in gold: The extended loop of the viral Ung in 5NNU (panel C) interacts with the DNA 
more intricately, compared to UNG2 (panel A). The apical leucine (also referred to as the pre-catalytic leucine residue) is shown in pink.	
* Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. 
Chem. 25(13), 1605-12 (2004). 
  
		
 The Ung catalytic domain 
Ung polypeptide backbone structures from the pdb may be readily aligned via structural superposition. 
The architecturally well conserved Ung catalytic domain is observed to be generally superimposable 
between representatives of evolutionarily disparate sources [29]. However, variant Ungs nevertheless 
differ in several respects, including alterations in even the most critical signature motifs involved in 
substrate engagement and catalysis, located in the C-terminal 200 ±c.20 residues (Figure 2).  
 
Motif 1 Motif 1 & 2 Motif 1 – 3 Motif 1 – 4 Motif 1 – 5 
     
A     B      C  
 
Figure 2 Conservation and variation in the key motifs involved in Ung substrate engagement and catalysis. 
Sequence alignment: The structure of the canonical Ung domain is highly conserved across large evolutionary distances but tolerates 
structural variation (e.g. HHV-4, HHV-8, and vaccinia) and key motifs show spatial and chemical variation (sky-blue background) that 
could be exploited for drug discovery. Motif 6 comprises the minor groove DNA binding loop, also referred to as the pre-catalytic loop 
(apical leucine residue on gold background, with vaccinia being the exception; note the vaccinia loop is structurally variant and also 
misses residues in deposited structures leading to uncertainty in alignment), which is sequestered by viral proteins that inhibit Ung. Note 
that the Ung catalytic triad (green background) is invariant in all examples shown here. The Ung domains aligned are in complex with 
either dsDNA (1SSP, 5NNU, 4QCB) or with the viral Ung inhibitory protein Ugi (1UDI, 2ZHX). Structural alignment of each structure with 
1SSP as the reference, was initially assisted by global superposition of Ung backbones using the software Chimera, and default settings. 
Structure depictions: The structure 1SSP (UNG2 in complex with dsDNA) with the DNA removed for clarity, is depicted as a cartoon in 
light blue, and motifs 1 through 5 from the sequence alignment are coloured in red sequentially from left to right. In the lower row, cartoon 
A depicts all 6 motifs from the above sequence alignment, shown in red. In all cases, the pre-catalytic loop leucine residue is shown in 
gold for orientation purposes. Cartoon B in the centre of the lower row is rotated so that the DNA binding surface of UNG2 is in the 
foreground, and the catalytic triad residues have been coloured bright green. The same view is depicted as a surface on the right of the 
lower row, labelled C. 
  
		
 Ung substrate engagement, and uracil specificity 
Ungs catalyse the hydrolytic cleavage of the N-glycosidic linkage between the pyrimidine base uracil, 
and the deoxyribose; catalysis can proceed in ssDNA or dsDNA substrates. In ssDNA the reaction is 
highly efficient, except in very short oligonucleotides, but even a dinucleotide can be utilised as a 
substrate [40]. In dsDNA the reaction is observed to be relatively slower than in ssDNA. As described 
below, this is likely due to necessary enzymatic motions and induced structural changes in the double 
helix. Hydrolysis of the N-glycosidic bond takes place in a concave pocket, exquisitely specific to uracil 
and some analogues, buried inside the Ung DNA binding cleft [3,41]. In order for uracil to enter the 
catalytic pocket, the target nucleotide must be extruded from the helical base stack [4]. This motion is 
facilitated by the dynamic structural nature of the search mode of Ung [42,43]. 
The structures of Ung catalytic domains in complex with dsDNA, demonstrate a subtle global closure of 
the domain upon occupation of the Ung DNA binding cleft (Figure 3). Detailed analysis of similarities 
and differences in domain closure under different circumstances implicates positions of possible 
interest in drug development [13,36,44]. The closure due to dsDNA has also shed light upon the mode 
of interrogation of DNA bases by Ung [42,43]. 
During substrate search mode, Ung engages dsDNA whereupon it introduces a local distortion to the 
double helix due to the shape of the Ung DNA binding cleft. Since Ung enzymatic activity does not 
require an external source of energy, the impact (via electrostatic attraction) and strain forces alone 
prove sufficient to drive the subtle and concerted motions that interrogate and catalyse substrate DNA. 
Due to the local dsDNA distortion induced by Ung binding, breathing motions of the DNA bases are 
exaggerated in the vicinity of dsDNA bound Ung: During breathing, the base pairs spontaneously break 
(due to distance and geometry fluctuations induced by natural compression/torsional motions of the 
DNA at large) then rapidly re-form. Base pairs involving adenine, namely thymine (under normal 
circumstances) or more rarely uracil (via misincorporation of deoxyuridine, except in specific biological 
contexts referred to in other parts of this article), are especially susceptible to exaggerated breathing 
during Ung binding. Also susceptible is guanine when mismatched with uracil. 
The exaggerated breathing of DNA bases permits the minor groove DNA binding loop of Ung to swing 
in and occupy the position vacated by a displaced base (as will be discussed, viral inhibitory proteins 
use DNA mimetic stealth to irreversibly trap this loop). In an Ung complexed with dsDNA, this loop 
motion also serves to boost progress of the displaced base towards the Ung catalytic pocket. The 
resulting arrangement results in a fleeting base pair mimetic contact to the remaining intrahelical base 
from the residue sidechain at the apex of the Ung minor groove DNA binding loop (typically, but not 
exclusively, leucine. N.B. This same apical leucine is irreversibly hydrophobically sequestered by viral 
Ung inhibitory proteins). With the lone intrahelical purine base thus stabilised, residency of the extruded 
pyrimidine in the Ung pre-catalytic complex, is prolonged. For brevity, this Ung leucine is alternatively 
referred to as the ‘pre-catalytic leucine’, and the minor groove DNA binding loop upon which this 
leucine resides, is elsewhere referred to as the ‘Ung pre-catalytic loop’. 
At the mouth of the Ung catalytic pocket, the presence of any pyrimidine 5-methyl group would meet 
with steric hindrance from a phenylalanine side chain. This allows a conserved Ung tyrosine residue to 
favourably stack with extruded thymine bases at a site external to the catalytic pocket. This blockade 
prevents the entry of thymine into the catalytic pocket under normal circumstances [3,13,43]. The result 
is that thymine will return rapidly to the interior of the DNA double helix. In contrast, the lack of a bulky 
methyl group at the 5-position of the pyrimidine ring means that uracil will pass unhindered into the 
catalytic pocket, where immediate water-mediated nucleophilic attack will efficiently remove it from the 
deoxyribose. Due to the structural arrangement of the catalytic pocket and its immediate exterior, 
cytosine will not be presented for catalysis due to unfavourable chemical properties, and purines would 
be sterically excluded from interrogation, altogether [3,4,42,43]. 	 	
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Figure 3 The Ung domain structure closes around dsDNA upon complexation (panel A), but not when viral Ung-inhibitory proteins 
complex with Ung (panels B – D). 1AKZ (gold) = apo form of UNG2; 1SSP (chain E, blue) = UNG2 complexed with dsDNA; 1UGH (chain 
E, purple) = UNG2 complexed with Ugi from Bacillus phage PBS1; 5JK7 (chain D, dark grey) = UNG2 complexed with Vpr from HIV-1. 
For clarity, dsDNA, and viral inhibitor proteins, respectively, have been removed. N.B. Uracil base has been included (bright pink) in the 
uracil-specificity (catalytic) pocket to appreciate its distance from the apical leucine (shown as stick) of the Ung pre-catalytic minor groove 
DNA binding loop, which is targeted by viral inhibitor proteins of Ung. 
Cartoon structures, rendered in Chimera, show UNG2 only: A – 1AKZ/1SSP, B - 1SSP/1UGH, C – 1AKZ/1UGH, D – 1SSP/5JK7 
  
		
2 Origins and significance of uracil-substituted DNA in pathogenesis 
Interestingly, uracil in a DNA context is important to pathogens both in terms of its promutagenicity, its 
effects on efficiency of viral DNA manipulation, and in avoidance of host surveillance. Uracil in a 
canonical DNA context is normally targeted for excision and repair. Uracil in canonical DNA occurs via 
either the spontaneous deamination of cytosine, or occasional misincorporation of deoxyuridine (levels 
of dUTP in normal cells are strictly managed to minimise the likelihood of its utilisation by DNA 
polymerases). However, the cellular immune repertoire may also introduce uracil, by enzymatic 
deamination of cytosine, for diverse fates. Furthermore, viruses of prokaryotes are also known to 
antagonise Ung, and even to deliberately bias or re-program the nucleotide biosynthesis pathways to 
preferentially utilise uracil in DNA as a replacement for thymine. 
 Cytosine is enzymatically deaminated in the innate cellular response to pathogen DNA 
Enzymatic deamination of cytosine to uracil in human cells, can be promoted by AID [Activation-
Induced (Cytidine) Deaminase] in SHM/CSR [8,9], or as considered elsewhere in this article, by 
APOBEC proteins [the Apolipoprotein B mRNA Editing Catalytic polypeptide-like family] in innate 
immunity contexts [45, 46]. This effect of cytidine deaminases in the innate immune context (e.g. 
APOBECs), is to severely compromise the sequence fidelity of pathogen DNA, also rendering it a 
substrate for enzymes such as UNG2. Problematically however, under particular circumstances this 
response appreciably amplifies the rate of cytosine deamination in general. This is thought to contribute 
to hypermutation, leading to carcinogenesis: This is a factor of relevance to any potential therapeutic 
interventions targeting UNG2 [47]. 
 Viruses can control uracil-substitution for survival and persistence strategies 
In viruses, uracil-DNA appears to be of some significance. For example, in HIV-1, integration of reverse 
transcribed viral DNA is sensitive to the degree of uracil substitution [7,48-50]. Furthermore, the level of 
uracil-DNA and its rate of removal are finely controlled by HIV-1 encoded proteins [51-57], possibly to 
promote a tolerable level of hypermutation to tune viral fitness in the host [46,58]. This important 
potential Achilles heel in the HIV-1 persistence strategy is elaborated elsewhere in this article. 
The a-, β-, and g-herpesviruses all carry a copy of a variant Ung, and in the latter two classes this 
appears essential to efficient viral lytic phase replication [59,60]. In viral genomic latency of HSV-1 (an 
a-herpesvirus), long periods in the form of an episomal DNA are typical. Latency occurs in terminally 
differentiated neuronal cells of the trigeminal ganglion, which do not provide maintenance via DNA 
repair. Therefore, it is conjectured that the role of Ung in reactivation from latency, is to make repairs to 
the viral genome during or in emergence from latency [61]. In g-herpesviruses, the virus encoded 
latency associated nuclear antigen (LANA) has been demonstrated to co-opt UNG2, presumably for 
maintenance during latency or in pre-lytic repair [62].  
Bacteriophages exhibit an ambivalent relationship to uracil-DNA, which nevertheless in all cases 
requires inhibition of Ung activity. Phages maintaining an entirely uracil-substituted viral genome [63-
65] or those sensitive to Ung-promoted nicking of spontaneous occurrences of uracil [66-70], must 
encode a gene product preventing uracil-DNA repair. Known examples stoichiometrically inhibit Ung 
directly (Table 2). There is biological analogy, therefore, between the retroviral requirement for 
accessory proteins manipulating Ung, and requirements of phage for an Ung-targeting protein. That is, 
the uracil-substitution state of the viral DNA is an important factor in successful viral propagation. 
Bacillus phage PBS1 comprises a genomic DNA of 0.25Mb wherein base pairing to adenine is entirely 
serviced via deoxyuridine instead of thymidine [63]. Ung has predictably devastating effects on such 
uracil-substituted naked DNA in the absence of other factors, reducing dsDNA to short oligonucleotides 
[6,71]. This degradative effect of Ung on highly uracil-substituted DNA is due to proximal removal of 
uracil on both duplex strands resulting in appreciable rates of spontaneous backbone nicking via beta 
elimination throughout the numerous abasic sites thus generated. In a cell, this catastrophic 
disintegration of the genome would be accelerated by the action of the BER response in the wake of 
		
Ung. BER first creates endonucleolytic breaks in the DNA phosphodiester backbone 5’ to the abasic 
site due predominantly to the action of host enzyme APE1/endonuclease IV. However, curiously in 
Bacilli, PBS1 phage replicate seemingly without any delays or untoward effects [66,72]. No Ung activity 
could be detected in viral lysates and this was ultimately traced to a single open reading frame in the 
phage genome encoding a protein, Ugi, which stoichiometrically and irreversibly inhibits Ung [22,73]. 
Table 2 Viruses and their utilisation of Ung.  
Virus type Relevance to Ung Interaction 
Bacteriophages: 
Phages with Uracil-DNA genome [Bacillus 
phages AR9, PBS1, and probably Yersinia 
phage fR1-37, and Staphylococcus phage 
S6], or with terminal-protein primed genome 
[picovirinae including Bacillus phage f29]; 
phages with ssDNA nicked genomes [i.e. 
PBS1 and other phages, e.g. coliphage T5]. 
[63,66-70] 
Ung inactivated by virally encoded 
protein. This prevents Ung from acting 
as an antiviral restriction factor. 
[22,55,67] 
DNA mimetic interactions from viral 
protein (Ugi in AR9 and PBS1; p56 in 
picovirinae) with residue-specific 
hydrophobic sequestration and 
inactivation of Ung. [16-21] 
Retroviruses (HIV-1) 
Uracil-substitution of the HIV-1 reverse-
transcribed genome demonstrated as an 
important factor for integration compliance 
[7,48-50], and in controlled mutagenesis for 
fitness in adaption to host [46,58]. 
Human Ung nuclear isoform UNG2 
inactivated by protein-protein 
complexation to virally encoded Ung-
targeting protein Vpr; also UNG2 is 
kidnapped by Vpr, and potentially also 
integrase, for diverse fates in virus 
maturation and cannot act as an 
antiviral restriction factor. [55] 
1) DNA mimetic interactions from viral 
protein Vpr, with residue-specific 
hydrophobic sequestration and 
inactivation of UNG2. [21] 
2) Interactions that employ UNG2 in an 
active form within the virion, 
possibly via integrase. [47,56] 
Poxviruses (vaccinia) [37,39] Specialised viral Ung. [26,27] Viral Ung essential for cytosolic viral 
replication. [39] 
Herpesviruses (a- e.g. HSV-1, b- e.g. hCMV, 
and g- e.g. EBV,KSHV) [59-62]  
 
Specialised viral Ung in lytic phase, 
and utilisation of UNG2 in the latent 
phase maintenance/reactivation. [3, 
33,34] 
Viral Ung is implicated in latent 
maintenance in HSV-1 [61], while in 
hCMV and g-herpesviruses viral Ung is 
an essential part of the lytic phase 
replication machinery [34,60,61]. In the 
latter class, UNG2 is recruited to assist in 
latency-associated processes [62]. 
 
 Control of DNA nicking in viral replication strategies requires viral command of Ung 
It makes some evolutionary sense to consider that Ung inhibition by viral proteins might have first 
arisen to protect another apparently more common mechanism of phage replication, not necessarily 
associated with utilisation of uracil-DNA: Specifically, the use of orchestrated single strand nicks [67-
70]. Such programmed single strand breaks appear to be a feature of unrelated bacteriophage 
genomes, relevant to specialised mechanisms of replication or/and encapsidation of nucleic acids. 
Stochastic deamination of cytosine leads, via Ung activity, to BER initiation and the appearance of 
random nicks. These random interlopers apparently poison finely-tuned, programmed-nick-dependent 
processes. This has a sufficiently negative effect on population size and fitness of viral progeny, that 
Ung-inhibiting proteins are deployed by such viruses [23,25,73]. 
 Uracil-substituted DNA in viruses as an offshoot of extant Ung silencing strategies 
Compromise of orchestrated nicking processes however, would appear to be a weakening phenotype, 
rather than a lethal one. Therefore, this lends logic to how or why viruses came to employ the curious 
and seemingly suicidal strategy of utilising entirely uracil-substituted DNA. If Ung-inhibition is deployed 
for nick-protection purposes, then global uracil-substitution of DNA can be adopted without danger of 
catastrophic genome disintegration. 
Uracil-substituted DNA imbues a different set of survival advantages, such as immunity to some 
restriction enzymes [74] and, by implication, firewalling from the cellular transcription program [65,75]. 
The latter tactic is analogous to well-studied transcription program isolation mechanisms employed by 
		
phages such as coliphage T7 [76]. The disadvantage is the metabolic trade-off, that viruses relying on 
uracil-DNA are genomic giants, encoding entire nucleotide biosynthesis modifying pathways, uracil-
DNA specific transcription apparatus, and their own uracil-biased DNA polymerase [65,77]. 
Ung inhibition has also been reported for the coliphage T5, which does not utilise uracil-DNA, but no 
reading frame encoding an Ung-inhibitory protein has been identified in the T5 genome to date [25]. 
The Ung inhibitory requirement in T5, is instead presumably linked to its programmed genomic single-
stranded nicks [70]. Interestingly when considering this line of reasoning, the giant phage PBS1 
features programmed genomic nicks, as well as comprising fully uracil-substituted DNA [63,69]. 
 Base substitution and Ung silencing by viruses compromises genomic encoding potential 
Precariously, in ultimate survival terms, inhibition of Ung activity effectively leads to abrogation of the 
most efficient pathway to uracil-DNA repair thereby steering viruses toward potential genomic 
extinction. Preventing the removal of deaminated cytosine applies inevitable attrition to the %GC 
content of genomes, due to fixing of C to T transition mutations through serial rounds of replication. The 
known uracil-DNA phages are all at the lower end of the genomic %GC spectrum (<30% globally, and 
significantly lower in some loci). Lowering %GC tends toward a series of survival boundaries: below 
each of which, the encoding of certain natural amino acids can no longer be achieved via the Universal 
Genetic Code. It is of note that many deposited phage genome sequences exhibit dramatically low 
global %GC, but published information about programmed nicks or genomic uracil-substitution is limited 
to very few phages. Known Ung-inhibitory encoding sequences are presently limited to those discussed 
in this article. Additionally, a far more complex parasite, Plasmodium falciparum, has a global 
genome %GC of only around 20%, yet counter intuitively with respect to the above reasoning, encodes 
its own Ung variant (Table 1). Plasmodium Ung has been a focus for drug discovery [38]. 
However, the tendency to lose cytosine positions to thymine, can in phages at least, also be explained 
by adoption of other base modifications to escape restriction enzymes. For example, adoption of 5-
methylcytosine as a substitute for the canonical base [78] (note that cytosine, and other pyrimidine 
derivatives, including hydroxymethylated, and glycosylated forms, have also been observed [79,80]), 
turns out to be a comparably dangerous strategy to the adoption of uracil-substituted DNA. This is 
because the rate of deamination of 5-methylcytosine is greater than that of cytosine, and the product is 
thymine rather than uracil [81]. To avoid fixing the mutation for posterity requires the pre-replicative 
intervention of mismatch-DNA repair. The upshot of this, is the sidestepping of a requirement for Ung-
mediated DNA repair. Cytosine derivatisation may therefore present a risky but workable general 
solution to the genomic %GC attrition problem. It may nonetheless be conjectured that the accelerated 
rate of deamination could potentially outstrip the capacity for mismatch repair (a slower process than 
Ung-BER) during an active phage infection. The likely picture is that Ung inhibition as a survival 
strategy will lead to inevitable transition mutations, and in turn, to pressures that adaptively evolve viral 
genomic sequences to retain, or substitute for, essential functions. 
 Horizontal transfer assists survival and mediates pathogenesis  
Of further relevance, is the possibility that, whether or not a phage genome is sensitive to Ung, the 
potential to inhibit Ungs may nevertheless be acquired horizontally. PBS1 is a transducing phage 
capable of infecting diverse Bacilli [82,83], as is another giant uracil-DNA phage, S6, with broad 
Staphylococcal specificity of infection [84]. The giant uracil-DNA phages: AR9 (also a transducing 
phage [85]), and PBS1, encode the Ung-inhibiting Ugi protein. A structural relative of the Ugi protein is 
Sa-Ugi, encoded by a phage-derived DNA in MRSA (Methicillin-resistant Staphylococcus aureus) 
Staphylococcal genomes. The origins of Sa-Ugi, which is mentioned in the following section, may 
therefore be via a phage like S6. 
The S6 genome has not been sequenced, but it is feasible that Ung-inhibitory genes may be 
horizontally transferred to bacterial genomes, and subsequently acquired by unrelated phages. Indeed, 
it is the case that strains of bacteria are known with unusual pyrimidine nucleotide biosynthesis and 
utilisation properties, related to lysogenic phage [86]. Thus, development of uracil-DNA or other non-
		
canonical DNA pyrimidine genome properties, in viruses, may be viewed as evolutionary survival 
strategies with origins in the inhibition of Ungs. Of interest to drug discovery directed at Ung activity, 
this has relevance to possible potentiation of drugs in tumours and also in bacteria. 
Extrapolating further, the suggestion is that uracil-DNA or/and Ung-inhibition mediated by phages could 
also be more widespread than is currently known [84,87], perhaps even including novel permutations of 
architecture and modes of interaction: This is important in the context of this review article, because 
any newly discovered natural Ung-inhibitory strategies might further inform new avenues to design 
novel chemical entities against Ung activity. Ugi, and Sa-Ugi, vary significantly when their sequences 
and structures are compared. Yet these natural differences, as well as differences that can be 
engineered (and may even exist in as yet unknown natural variants) could point to unique ways to 
target pathogen Ungs, or even the host enzyme [88]. Indeed, the sequenced p56 type Ung inhibitors 
vary in sequence within the conserved region (Figure 4). 
 
Figure 4 Variation within the conserved region of virus-encoded p56-type Ung-inhibitory proteins. In the rightmost column, the protein 
sequence accession number is given: note, that in the case of the B103 protein, this is a nucleotide sequence accession (cyan letters) 
because the p56 ORF does not appear in the genome annotation. The B013 p56 is the translation product of the reverse complement 
between nucleotides 488 and 658. 
Sequence alignment was performed with default settings at the Clustal Omega web server, then manual curation was performed using the 
p56 protein structure as a guide in Chimera (inspection of chain D from 4L5N). Residue colours and scoring of matches in the form of 
symbols below the alignment are Clustal Omega defaults (Gonnet PAM 250 matrix). The pair of u symbols above the alignment show 
the hydrophobic residues that, in the context of the dimerised protein, trap the Ung pre-catalytic loop leucine residue. The phylogenetic 
tree at the left of the figure was generated with Clustal Omega*, and is a default Neighbour-joining tree without distance corrections.	
* Sievers F, Higgins DG. Clustal Omega for making accurate alignments of many protein sequences. Protein Sci., 27(1), 135-145 (2018). 
  
		
3 Motivations for specific targeting of Ung variants via synthetic novel chemical entities 
Considering differences in key Ung motifs, those in motif 5 (Figure 2) are likely sufficient to enable the 
development of specific novel chemical entities to target them. 
 Bacterial Pathogens 
In the case of pathogenic states of commensal bacteria, inhibition of microbial Ung could in principle be 
used to potentiate the action of compounds that cause lethal DNA damage in the absence of Ung. The 
key residue type or geometry nuances between UNG2 and those of, for example, pathogenic 
Mycobacteria (Figure 2, Table 1) could permit the possibility of development of selective Ung inhibitors 
[35,36,44]. These differences include markedly different interaction profiles for Mycobacterial Ung, 
versus UNG2, when either is complexed with the virus-encoded inhibitor protein, Ugi [35]. Ugi, and 
mechanistically analogous proteins (Table 2) like p56, and Vpr, as well as Sa-Ugi (also described 
immediately below), are proposed in this article as mechanistic templates upon which to base new 
forms of Ung inhibiting novel chemical entities. 
In one pathogen of acute healthcare interest, the picture is intriguing: MRSA Staphylococci harbour 
fragmented phage remnants within the pathogenicity island [24], including a gene that in recombinant 
experiments encodes a functional Ung inhibitor [20]. Could this Sa-Ugi gene be active? It would in all 
likelihood cause genomic sequence fidelity maintenance to be compromised in the host if its product 
Sa-Ugi were expressed, because it would suppress Ung base-excision repair. Such an effect might in 
part contribute to the extreme plasticity of SCCmec (staphylococcal cassette chromosome mec) 
pathogenicity islands [24]. It could be conjectured that Sa-Ugi expression is conditional on some 
metabolic status or stress. If any such triggers exist, then proto-therapeutic induction of Sa-Ugi might 
potentiate the action of DNA-damaging drugs that are potent in the absence of Ung activity. This type of 
strategy would result in selective toxicity to MRSA pathogens, which is an intriguing thought indeed. 
 Cancer 
Related to the above conjecture, there is precedent, with notable success in potentiation of DNA-
damaging drugs as a strategy in cancer chemotherapies, via poly(ADP-ribose) polymerase (PARP) 
inhibitors (reviewed in [89]). Considering the above, similar targeted deployment of UNG2 inhibitory 
compounds [7,8] to tumour sites is therefore also an attractive proposition. 
 Viral pathogens 
Viral pathogens (Table 1, Table 2), such as all (i.e. a-, b-, and g-) herpesvirus families [59-61] and the 
poxviruses [39], have genomically acquired and adapted Ung as a central and even indispensable part 
of the viral replicative or latency processes. Ung is therefore of importance to these viruses [90], and 
exploiting the catalytically important structural differences between host and viral Ungs presents a bona 
fide target for synthetic antiviral development. 
  a) Vaccinia 
The poxvirus vaccinia Ung is radically variant, in that it has adapted to an essential role in viral 
replication processivity and fidelity, via PPI with the viral polymerase. Vaccinia Ung also contains a 
structurally altered pre-catalytic loop, which lacks an apical leucine [26]. Both of those features differ 
from almost all other canonical Ung domains, which feature a hydrophobic (leucine, or in some Bacilli, a 
phenylalanine) side-chain apical on the Ung pre-catalytic loop. Vaccinia Ung (also known as, viral 
protein D4) is also required as an essential subunit by the viral (protein E9) DNA polymerase: Without 
the involvement of D4 in viral replication, vaccinia is not viable [26-28,39], which presumably applies to 
all poxviruses given their overall similarity in these encoded subunits. Furthermore, UNG2 cannot 
rescue the situation for the virus, which in any case replicates in the cytoplasm (note again that UNG2 
is an Ung isoform localised in the nucleus). The implications for antiviral potency are thus obvious, and 
indeed small molecule targeting of the D4-E9 PPI interface disrupts viral DNA synthesis in vitro [28] 
(and reviewed in [26,27]). The suggestion is poxviruses are highly mutable and able to cross species 
		
barriers, therefore future therapeutic need is not out of the question, even if smallpox outbreaks may 
essentially be ruled out under normal conditions [91]. 
  b) Herpesviruses 
The three types of herpesviruses, a- (e.g. HSV-1, HSV-2, VZV), b- (e.g. hCMV), and g- (e.g. EBV, and 
KSHV), regardless of host cell, all contain viral genome copies of Ung [59-61]. These viral Ungs differ in 
sequence from the host enzyme in all cases, but essentially retain the hallmark architectural 
conservation in structure observed across all known homologous canonical Ungs (Figure 2). The most 
overt variants are Ungs from the b-, and  g-herpesviruses. Structural information is lacking for b-
herpesvirus Ungs, which precludes detailed analysis. In the g-herpesviruses, Epstein-Barr (EBV) [HHV-
4] and Kaposi’s sarcoma-associated herpesvirus (KSHV) [HHV-8], the pre-catalytic loop of Ung is seen 
to be appended by a sequence motif of conserved length but variable composition (Figure 2). Structural 
studies reveal that upon DNA docking this elaborated motif adopts a conserved structure [33,34] 
(Figure 1). In engineered mutant forms of g-herpesvirus Ung, lacking the loop motif appendage, 
infecting viruses are highly compromised in lytic phase replication [60,92] and equivalent mutants are 
rendered biophysically unstable [34]. Targeting the structural underpinning of the extended loop 
conformation, or its dynamics, with novel chemical entities, would be expected to result in a similar 
disabling phenotype: The viral lytic phase of g-herpesviruses can thus be considered druggable via 
Ung. 
The picture is somewhat complicated by the presence of dual OriLyt foci in g-herpesviruses, each 
associated with support of viral replication in different cell types [93,94], thus the strategy may not be 
applicable to all infected cell types. However, given the variety of health complications (e.g. Infectious 
mononucleosis, Burkitt’s Lymphoma, and Nasopharyngeal Carcinoma, in EBV; Primary Effusion 
Lymphoma, Multicentric Castleman’s Disease, and Kaposi Sarcoma, in KSHV) caused by these viruses 
however, being able to target at least some of these debilitating, pathological, or carcinogenic 
conditions would nevertheless be worthwhile. In a final twist, g-herpesviruses, co-opt UNG2 during 
latency for latency-associated maintenance processes and to preserve DNA sequence fidelity in the 
viral episome [62]. Therefore, mapping the UNG2 protein interactions with viral factors, opens the door 
to drugging the host enzyme as a therapeutic option. This would be expected to impact latent episome 
integrity to reduce viral load [7,8,15]. 
 Ung inhibitors to counter virus-associated neurological decline? 
Finally, both a- (e.g. HSV-1, VZV), and b- (e.g. HHV-6A, HHV-7) human herpesviruses have been 
implicated as aetiologic agents in dementias and other neurological conditions (reviewed in [95]). An 
increased array of options in small molecule therapeutics that prevent formation of mature virions would 
therefore be useful. Could small molecules efficiently targeting viral encoded Ung in neurons and 
beyond the blood brain barrier be conceived? In fact, the similarities with HIV-D, a viral dementia 
associated with HIV-1 infection are noted (reviewed in [95]), and fall into the same therapeutic category. 
As will next be discussed, drugging UNG2, or virally encoded factors associated with it, is an attractive 
option.  
  c) HIV-1 
HIV-1 is a major human viral pathogen of relevance when considering potential therapeutic targeting of 
Ung (Table 1). In contrast to the viral examples discussed so far, HIV-1 does not encode an Ung, but 
rather it encodes proteins modulating Ung localisation, availability and function [96]. The HIV-1 
encoded accessory protein Vpr is able to associate by formation of complexes with various human 
cellular protein targets, including UNG2 [51,97]. 
Interestingly, Vpr apparently serves multiple diverse ends with its UNG2 hostage: Predominantly, it 
targets UNG2 for destruction by associating with DDB1–DCAF-1, thus delivering UNG2 to the CRL4 
proteasome degradation complex [21,53,55]. Vpr additionally transcriptionally downregulates Ung (Vpr 
is comprehensively reviewed in [98]). It is known that the degree of uracil-substitution of DNA is critical 
		
for reverse-transcribed viral genome integration into host genomic material [7,48-50]. UNG2 could 
clearly interfere, which makes sense of its Vpr-mediated downregulation (including by specific 
transcriptional suppression [54]). 
Intriguingly then, UNG2 also appears to be inserted into HIV-1 virions along with Vpr [52] or/and 
potentially via its independent association with HIV-1 integrase [99] This is suggested to make use of a 
non-enzymatic function of UNG2, along with the p32 subunit of the host RPA complex, important for 
viral fitness during reverse transcription and for the optimisation of cDNA integration [49,56,57]. In 
terms of the importance of UNG2-specific PPIs, this is somewhat analogous to non-enzymatic roles for 
both viral Ung, and UNG2, in herpesvirus replication strategies. 
A chemical or peptide, designed to inhibit UNG2 association with Vpr, ought to be detrimental to HIV-1 
fitness [100]. It is also noted here, that natural plant extracts acting as general inhibitors of Vpr have 
been reported [101]. Any general Vpr-inhibiting compounds making it into the clinic would have the 
potential to compromise HIV-1 viability fairly comprehensively [102]. It should be noted that Vpr, in 
common with other accessory proteins, is under selective pressure following initial infection and 
[presumably active] variants are easy to find in the databases (Figure 5) [103]. As will be explored next, 
UNG2 and its essential PPIs in HIV-1 maturation, are of parallel interest as potential targets for 
antiretroviral therapy. 
 Reasons to target UNG2 in the context of HIV-1 
Curiously, it would appear that HIV-1 may also mediate its own genetic drift via virion located UNG2. 
However, UNG2 kidnapped by Vpr is likely to be enzymatically inactivated via stoichiometric inhibition 
[21,49]. It is therefore presumed that this active virion-associated form of UNG2 is a fraction reported to 
be recruited via HIV-1 integrase, and essential to viral genome integration [99]. Limited mutagenesis 
inside the virion involving UNG2 is enacted in concert with host APE1, and is likely at least partially 
reliant on the prior activity of another host restriction factor APOBEC3 (specifically, isoforms F or G, 
when recruited to the virion, in the absence of the viral antagonist HIV-1 accessory protein Vif) [46]. 
APE1 is part of the ER-associated SET complex (APE1, NM23-H1, TREX1) reported to associate with 
the HIV-1 preintegration complex, and important in HIV-1 defence against autointegration (a suicidal 
complication of retroviral DNA integration, wherein the viral DNA fruitlessly integrates with itself) [48, 
104]. APOBEC3 isoforms F and G, are molecules of innate cellular immunity against viruses that enter 
the cell. APOBECs cause deamination of cytosine bases in ssDNA at replication or transcription 
complexes [45,47], and the resulting uracil would be a substrate for UNG2, normally leading to viral 
genome disintegration, as described earlier. However, HIV-1 retains its RNA genome within the capsid 
core particle, thus enacting reverse transcription in situ, which must aid in shielding the viral nucleic 
acids from DNA sensing (a trigger of innate immune response) and thus innate immune compromise 
[105,106]. 
HIV-1 could therefore be described, analogously to DNA phages using non-canonical pyrimidines such 
as uracil, as living on the edge: Using its multi-tasking accessory proteins, Vpr and Vif, to deplete 
cellular resistance factors that would normally destroy it. HIV-1 re-contextualises UNG2 and APOBEC 
proteins, as well as the SET complex, to optimise its survival [107,108]. Fractions of these host 
restriction factor populations remain active, apparently deliberately recruited within the capsid. The 
virus is thereby pushed even closer to the brink of extinction and yet is able to profit from selection of 
sub lethal hypermutated genome states [46,58]. As an antiretroviral strategy with novel chemical 
entities, targeting UNG2 PPIs with the HIV-encoded proteome, would therefore be expected to promote 
a twofold effect: First, to negatively impact the probability of viral genomic integration due to the 
requirement for active captive UNG2 by viral integrase, and second, to radically skew genetic drift 
towards non-viability in viral progeny due to consequent unrepaired cytosine deamination in viral cDNA 
produced by APOBEC3F/G. 
  
		
4 Convergence on a universal Ung-inhibitory mechanism by unrelated virus proteins 
Both prokaryote-specific and eukaryote-specific viruses, inhibit, antagonise, or co-opt Ung, as would be 
expected of a ubiquitous molecule of innate cellular immunity (Table 2). Stoichiometric and irreversible 
inhibition of Ung enzymatic activity has, to date, been observed in bacteriophage encoded DNA 
mimetic proteins. These are Ugi, and p56 [15-19], as well as Sa-Ugi (a horizontally transferred phage-
derived structural relative of Ugi, residing in a transposed pathogenicity island of a bacterial genome) 
[20]. The structure of Vpr in complex with UNG2 would strongly suggest inhibition of nuclear-localised 
UNG2 activity is also a strategy of the HIV-1 virus [21].  
 
 
A 
 
   
 
 
B 
 
   
 
C 
 
   
D 
 
 
 
 
 
 
 
 
 
 
	
Figure 5 Evolutionarily disparate protein structures utilise an analogous structural mechanism to sequester and inactivate Ung, through 
convergence upon spatially precise residue contacts.	Within each structural class of Ung inhibitor, interacting residues are subject to 
substitution in different strains. 
Sequence alignment: Left column. DNA mimetic residue contacts are made by the motifs shown on a sky-blue background; grey font 
indicates those positions not in contact with Ung in deposited structures. Residues indicated “~” can be substituted in related sequences. 
The Ung minor groove DNA binding loop leucine [or its equivalent] is sequestered by residues at positions with a red background. 
		
A For Ugi, in the top row, there are no variant sequences yet known. B In the next row, there are several Sa-Ugi sequence variants 
(indicated “~”) from sequenced Staphylococcus genomes: all of which, it is presumed, are able to inhibit Ung. C In the p56 row, there is a 
residue shown on a gold background, forming the base of the leucine sequestration pocket, which can vary in related sequences; 
tolerable variation is probably explained by the fact this residue does not make contact with the leucine. Interestingly, there are p56 
sequences in which every residue other than those directly interacting with the Ung leucine, vary (indicated “~”) with respect to the known 
structures; there is probable structural equivalence in spite of such sequence plasticity, which will be of relevance in drug design targeting 
the Ung DNA binding cleft. D In the Vpr row, it is clear that key contacts may tolerate residue changes (indicated “~”) which are observed 
in sequences throughout the major HIV-1 groups (M – with subtypes indicated by the second letter, N, O, P, and U) and close relatives 
HIV-2 (labeled “2”) and SIV (labeled “S”). Grey font indicates residues that are not in contact with Ung in 5JK7; it is noted that such 
residues are relatively more prone to substitution in Vpr sequences from included groups, for the purposes of clarity this variability is not 
indicated by symbols in this view. Sequence data for Vpr were accessed from: HIV sequence database, at 
https://www.hiv.lanl.gov/components/sequence/HIV/search/search.html   
Structure depictions, rendered in Chimera, illustrate analogy in residue arrangements for Ung-complexation in spite of architectural 
diversity. The keynote is versatility in generating effective Ung inhibition, which alludes to the possibility of development of specific novel 
chemical entities to target specific Ungs in diverse relevant pathologies. Cartoons coloured as follows: Gold for residues involved in DNA 
mimetic contacts with Ung, red for hydrophobic residues that sequester the apical (predominantly, leucine) residue on the Ung pre-
catalytic loop. In p56 the DNA mimetic monomer subunit in this dimeric structure is coloured in dark blue as per the monomeric proteins in 
the other rows, while the partner monomer, primarily involved in completing the leucine sequestering hydrophobic cavity makes relatively 
few contacts to Ung, and is coloured light grey. In the leftmost column of structure triptychs in each row, is a cartoon to show side chains 
involved in contacting Ung. The same view in the middle column of each triptych shows a view of Ung-contacting surfaces. In the 
rightmost column of the structure triptych is the same surface view, with coulombic potential indicating the charge alignment propensity of 
these markedly acidic proteins, to the appreciably basic Ung DNA binding cleft. 
Those viral genomic protein inhibitors of Ung are essential to viral replication. Vpr variants are known in 
the major groups and sub-types of HIV-1 and also related retroviruses (Figure 5). The NMR structure of 
the apo form of Vpr [109], in common with initially reported NMR structures of Ugi and p56 [110,111] 
did not permit detailed modelling of the PPI interface with Ung. The interaction of Vpr with UNG2 has 
been variously explored (Vpr is comprehensively reviewed in [98]), implicating the essential contribution 
to complexation with UNG2, of the Vpr tryptophan 54 residue [100]. The crystal structure of the Vpr 
complex with UNG2 and DDB1–DCAF-1, revealed striking mechanistic analogy in Ung sequestration to 
the previously described phage-derived proteins [21], and Vpr tryptophan 54 indeed makes a key 
contact to UNG2. 
The converged Ung inhibitory mechanism deployed by these evolutionarily disparate virus-encoded 
proteins, has the following common features: The known Ung inhibitor proteins are typically less than 
16kD and markedly acidic in character [16-21,108]. Ung inhibiting proteins utilise (1) a charge-based 
alignment to orient on the Ung DNA binding cleft, then (2) Ung-specific DNA mimicry, docking to the 
Ung DNA binding cleft, and finally (3) hydrophobic sequestration of an Ung residue essential for pre-
catalytic dsDNA substrate stabilisation [16-21]. This final capture step effects stoichiometric inhibition of 
Ung, irreversible under normal cellular conditions [19]. Despite a lack of sequence and structural 
homology between the Ung inhibitory protein classes (Figure 5), the mechanism operates equivalently 
and affects a wide range of known Ungs when tested in vitro [16-22,36,66,67,72,73,88]. Reassuringly 
for the purposes of emulating this mechanism for drug discovery, the various viral Ung inhibitory 
proteins interact differently in precise terms with their biological targets and furthermore in an Ung-
dependent manner. An array of deposited biological structures are known, involving different viral Ung 
inhibitor proteins in complex with both UNG2 or a variety of pathogen Ungs (Figure 1, Figure 6). Thus, 
detailed insight for design, and increased scope for selectivity, should be achievable should it prove 
possible to emulate aspects of this Ung-inhibitory mechanism in the guise of novel chemical entities. 	 	
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Figure 6 Analogy in mechanism to sequester and inactivate Ung. Convergence upon equivalent functional protein chemistry in the 
unrelated protein architectures evolved in discrete viral genomes.	Within each class of Ung inhibitor, specific contacts to Ung differ, but 
retain the functional DNA-mimetic mechanism for Ung sequestration and nullification of activity. 
Structure cartoons (1UGH chains E-I, 1AYR chains A-B, 4L5N chains B-E-F, 5JK7 chains D-F), rendered in Chimera, illustrate occupation 
of the Ung (light blue) DNA binding cleft (light blue sticks), and sequestration of the pre-catalytic Ung leucine (gold sticks) in spite of 
architectural diversity between the inhibitor proteins (dark blue). Effective Ung inhibition via inhibitor hydrophobic residues (red sticks), 
involves DNA mimicry (pale yellow sticks). One structurally identical monomer subunit of p56 (light grey), although essential for Ung 
inhibition, plays little part in DNA mimicry. That role is served by the Ung-docked DNA mimetic (dark blue) monomer subunit; the dimeric 
interface effects Ung inhibition by p56. 
DNA mimicry involves contacts to the Ung DNA binding cleft using inhibitor protein amino acid 
sidechain chemistry to emulate parts of the bonding pattern encountered by Ung when resident upon 
dsDNA [16-21,88]. Ugi and Sa-Ugi utilise the edge of a beta strand to convey DNA mimicry, p56 utilises 
the alpha-helix of one of its monomer subunits, and Vpr employs a variable loop between two helices. 
All proteins contain a localised depression on the surface, lined with hydrophobic residues to trap the 
Ung pre-catalytic leucine (a phenyalanine in Bacilli) residue (Figure 5, Figure 6). The modified loop in 
poxvirus Ung cannot be sequestered, and it is untested as to whether the positively charged arginine or 
lysine residues found as substitutes for leucine only in b-herpesvirus Ungs could be captured. Certain 
similarities in charge distribution, and protrusion of contacting residues, are observable when the Ung-
facing surfaces of the structurally described proteins are compared (in Figure 5, see the rightmost 
columns depicting surface views). This represents a remarkable level of analogous, spatially precise 
protein chemistry by functional convergence originating from radically different protein architectures 
[16-21]. 
 
Figure 7 Variant Ungs of herpesviruses feature differences in the pre-catalytic loop region, of potential importance to drug design. 
Sequence alignment: The structure-based sequence alignment spacings (against 1SSP as the reference) originally shown in Figure 2, 
are retained for the alpha- [HHV-1], and gamma- [HHV-4, and HHV-8] herpesvirus sequences in this alignment of the pre-catalytic loop 
motif (i.e. referred to in Figure 2, as Motif 6). To compare with the beta-herpesviruses [HHV-5, HHV-6A, and HHV 7], for which there is 
currently no representative structure deposited in a public database, a manual alignment of the same pre-catalytic loop region (i.e. Motif 6 
in Figure 2) is added. Notably, aside from some elaboration involving the loop length and residue composition (cyan coloured lower case 
text), there is a charged residue in the place where a hydrophobic residue is normally found in canonical Ung sequences (this residue is 
shown in Clustal Omega default colouring). This substituted position has obvious implications for building specificity into inhibitor design. 
How then, might new inhibitors of Ung be designed? Targeting Ung for chemical inhibition is not a new 
endeavour [10-15,28,38], and atomic resolution insights for Ungs are plentiful (the PDB at the time of 
writing returns 99 structures with the search term “3.2.2.27”, and 199 structures with the search term 
“ung”). These deposited structures include evolutionarily diverse Ung domains in the apo form, and in 
		
complex with natural and synthetic ligands as well as with the known viral inhibitor proteins: Ugi, p56, 
Sa-Ugi, and Vpr. Perusing just those structures alluded to in this article, reveals differences between 
Ungs in the details of ligand-bound forms that could be exploited in drug discovery. To summarise 
these very broadly: (1) A tightly bound blockade of any suitable site in an Ung DNA binding cleft could 
prevent association with DNA, and thus would have a silencing effect on Ung activity. (2) Alternatively, 
blockade of PPI interfaces on Ung, or its viral proteome ligands, would lead to weakened viral 
processes related to replicative fitness. 
  
		
5 Synthetic selective Ung inhibition and future trends 
It is worth recalling at this point, that classic drug design of the early 1990s developed a uracil-analogue 
compound with a hydrophobic tail that occupied the uracil-binding pocket in the Ung catalytic site. This 
was particularly aimed at herpesvirus encoded Ung, specifically from the a-herpesvirus HSV-1 [HHV-
1]. These efforts have included multiple attempts at development of series of synthetic inhibitor 
compounds [10-15]. The approach has been one of targeting the exquisite affinity of Ung for uracil, and 
building in hydrophobic character, which according to modelling studies, may provide an analogous 
effect to the natural virally encoded polypeptide inhibitors of Ung [14]. The issue with the inhibitors 
described is not in their relative selectivity for the viral Ung over UNG2, which was found to be suitably 
distinct (reported to be at 8µM vs 300µM in the original OctAU inhibitor molecule) [10,11]; the inherent 
hydrophobic character of the molecules is more the problem to overcome as a key issue in compound 
development. 
Subsequently developed compounds have similar properties [12-15], with those latter studies indicating 
the hydrophobic portion of the compounds enters a site interior to the enzyme through the catalytic 
pocket, rather than akin to the viral proteins’ targeting of the pre-catalytic leucine residue. Such 
compound series therefore contrast with the natural inhibitors encoded by viruses, which do not occupy 
the uracil-binding pocket. Avoiding uracil analogues would be advantageous, since these would likely 
cause toxicity issues associated with DNA intercalation propensity; additionally, hydrophobic tails do 
not suggest the most favourable drug like properties. 
Thus, the Ung pre-catalytic loop, and the DNA binding cleft area exterior to the uracil-specific catalytic 
site, would appear to be the key inhibitory weak point of Ung from an evolutionary antagonistic vantage 
point. It is natural then to suppose that variant Ungs, differing as they do in this key respect of Ung 
structure and chemistry conservation (i.e. Motif 6, in Figure 2), would represent start points for inhibitor 
design. To reiterate, the structurally and chemically variant analogous loop in vaccinia Ung is one 
reason why Ugi has no inhibitory action against that particular Ung variant. However, from a specific 
drug design perspective that feature alone would represent a unique targeting opportunity. In this case 
it would represent an alternate approach from targeting the PPI with vaccinia polymerase E9 [28]. The 
different pre-catalytic loop chemistry (arginine or lysine, rather than leucine) found on b-herpesvirus 
Ungs would suggest yet another unique feature to target on a pathogen variant Ung, relative to UNG2. 
 Transposing natural Ung-targeting via modern drug design for key therapeutic areas 
It is hoped that three things will now remain in mind when considering design and synthesis of 
healthcare-transforming Ung inhibitors: 
1) The first is that Ung is an actual or potential Achilles heel to be targeted in at least several pathogens 
(Table 1) responsible for current worldwide critical healthcare burdens; including those mentioned in 
this review, namely: Tuberculosis, MRSA, malaria, herpesviruses, and HIV-1, noting also that viral Ung 
would make an excellent addition to compounds targeting poxviruses, and furthermore that UNG2 in 
certain pathological contexts (its PPIs in viral diseases, and its activity in cancer) is also a therapeutic 
target. 
2) The second is that Ung selectivity has been demonstrated via classic drug discovery approaches 
from the 1990s, and with the wealth of structural information now in our hands also via structure-led 
fragment-based drug design methods. The emphasis to date has always been on starting with uracil or 
its analogues [10-15].  
3) The third consideration is the importance of Ung in pathogenically relevant PPIs, and the convergent 
DNA-mimetic mechanism of natural virally encoded Ung inhibitor proteins, thus uracil is not the only 
way forward. Concepts of drug design that target PPIs, have been shown to be viable (reviewed and 
discussed in e.g. [112]). Furthermore, new approaches to the targeting of DNA-binding proteins 
specifically, could in principle (1) close the Ung catalytic domain or (2) reprise elements of the DNA 
mimetic protein mechanism or interfering with the pre-catalytic loop, which is not the case in drug 
		
designs explored to date [10-15]. In fact, the Ung DNA binding cleft in general could offer selective 
druggable sites that could be highly specific and tight binding. A summary and consideration of the 
components that would support this approach is presented here to conclude this article. 
 From protein mimics of Ung-bound DNA, to peptide mimics, to therapeutics? 
Three unrelated protein architectures: Ugi/Sa-Ugi, p56, and Vpr, have zeroed in on a single universal 
mechanism for inhibition of Ung activity [16-21]. Even within each class of Ung inhibitor, sequences 
vary within the Ung-contacting motifs and yet retain the functional mechanism for Ung sequestration 
and nullification of activity (Figure 4, Figure 5, Figure 6). Elements of this evolutionarily road-tested 
sweet spot for Ung silencing remain to be exploited in the search for Ung-specific novel chemical 
entities, yet the potential therapeutic vistas to be thus opened appear tantalising. 
Considering also, PPIs: disrupting them with novel chemical entities may progress from mapping out 
druggable patches at the contact interfaces using peptides [113]. This strategy in itself may result in a 
drug-like molecule, since peptidic drugs are successful in their own right (as reviewed in [114]). It is 
possible that a suitable peptide docking in the Ung DNA binding cleft may elicit closure of the Ung 
catalytic domain. Thus, a peptide therapeutic to act on Ung, can quickly be sketched out; but, the 
question is, how specific or general can such an imagined Ung inhibitor be? The answer is, probably 
more inter-species specific than an inhibitor based upon uracil. DNA binding clefts in diverse Ungs 
display ample sequence variation, observed as attributable conformation changes. Indeed, residue 
conformation in proteins is known to underlie sequence variation that nevertheless supports structure 
conservation [115], thus it stands to reason that the landscape for drug binding would be appreciably 
different in such homologues if the cleft were targeted rather than the pocket. To reiterate: uracil 
analogues need not be part of the equation at all, in principle. 
The Ung DNA binding cleft need not be fully occupied to trigger domain closure, since closed 
conformations of Ung have been observed under different circumstances [44]. Thus, the drug we can 
envisage in development could be based upon a molecule arising from a library that samples the cleft 
area of Ung, and for which domain closure, or just tight binding, is the readout of interest. In fact, similar 
strategies in compounds based upon uracil binding have been shown to be useful approaches [13]. 
This could yet be a peptidic molecule, however new approaches in effecting DNA mimicry for protein 
interaction using aromatic oligoamides, might also offer an alternative [116]. 
The apical residue on the Ung pre-catalytic loop is almost always hydrophobic (almost always leucine; 
see Figure 2) but, in an imagined novel chemical entity emulating that residue’s sequestration by virally 
encoded inhibitors, binding could instead target another type of chemistry relevant to that loop.	In 
principle, such inhibitors could emanate from a scaffold that takes advantage of cleft differences 
between Ungs, heralding specificity for any selected Ung. Interestingly, although it has already been 
effectively targeted via its PPI with viral polymerase E9, the poxvirus Ung has a structurally diverged 
loop, among other gross differences relating to its essential role in viral replication [26]. The b-
herpesvirus Ungs feature a charged apical pre-catalytic loop residue; g-herpesvirus Ungs have a 
separate character to take advantage of in this pre-catalytic loop area, by virtue of a structured 
extension to that loop, necessary for effective lytic replication [33,34]. In terms of designing a drug, this 
has a slight complication in that the loop is disordered prior to DNA docking; nevertheless, the structural 
and mutagenesis data available provide important design clues [34]. 
Looking at the HIV-1 accessory protein Vpr, its interactions with UNG2 show a different bonding pattern 
in the Ung DNA binding cleft, supported by extra interactions on the surface around it [21]. Again, this 
could provide more clues as to how to build a novel chemical entity which effects uracil-free inhibition of 
Ung, as in effect this structural insight provides some pre-prepared peptide mapping [113]. There are 
PPI interfaces to define, other than Vpr, which could be sites for important new UNG2 targeting drug 
approaches against HIV. In particular, the details of a reported association with integrase [99] have not 
been described to date. 
  
		
Conclusion 
Ungs are key molecules in a number of important pathological states. Therefore, the time could be right 
to open potentially very useful avenues for novel therapies targeting Ungs, with new advances in drug 
design and delivery. It is suggested these could now enable NCE emulation of independently evolved 
viral Ung-targeting strategies via PPIs, including Ung inhibition. 
Importantly this Ung-inhibitory mechanism does not involve the uracil-selectivity of Ung. There are 
currently no novel chemical entities that do not target uracil-binding, to exploit key features of the 
natural Ung-inhibitory mechanism, but the potential for increased selectivity by exploring this path 
seems highly attractive. There is relative variability in the cleft region of Ung involved in interaction with 
viral inhibitors, and variation too in the contact features of those inhibitors. 
Furthermore, PPIs involving either UNG2 or virally encoded Ung, appear central to pathogenic virus 
viability and present another therapeutic horizon. The utility of targeting Ung PPIs has been 
demonstrated with poxvirus Ung: This approach could therefore be applied to more immediately 
relevant pathogenic viral states, such as those caused by human herpesviruses, or HIV-1. 
Future Perspectives 
It is envisaged that developments in AI-enhanced bioinformatics will provide greater power in 
uncovering currently hidden sequence and structure signatures. Such tools could discover proteins 
interacting with Ungs in ways that promote or support pathogenesis. The evolutionary insights provided 
by an expanded known universe of pathogen interactions via Ung, will assist development of potent 
novel chemical entities capable of disabling specific or multiple pathogen Ungs, or even UNG2 where 
more appropriate. The chemical state of the art will enable targeting of Ungs into specific cells (e.g. via 
antibody-drug conjugates) and intracellular locations, or to promote their uptake into pathogenic 
organisms. 
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